Theriva Biologics Inc (TOVX) Stock Price, Quote & News

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for trea...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 417 4364

Website: therivabio.com

Address:

9605 Medical Center Drive, Suite 270, Rockville, United States

RoyalImperial Apr. 25 at 5:32 PM

MITQ ✅ Has that look for next week, one of the most undervalued and cleanest micro caps. Latest news + contracts rolling in Low float (6M) NO dilution Record earnings trend 📈. A $9M projector refresh contract plus other large projects shifting into FY2026 means a significant revenue surge is likely already locked in and coming. $TOVX $CVV $KLXE $INBX ww..

0 · Reply

AssasinLife Apr. 25 at 1:58 AM

$MITQ nice volume came here today, something is obv brewing. Usually news comes along, they haven't released one a while 👀 $RPGL $TOVX .

0 · Reply

TheDipMaster Apr. 25 at 1:21 AM

$TOVX up or down to fill gap at .26 level assuming no bad news. Keep an eye on $DVLT they generate revenues and might break out to 1.5+ if no bad news lol. Can’t trust any of these companies. All you can do is hope for the best. I honestly like Dvlt better since they already have real products associated with AI . Whereas tovx is still a waiting game.

0 · Reply

RoyalImperial Apr. 24 at 9:47 PM

MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $TOVX $VTAK $SOWG $CHOW ww./..11

1 · Reply

Raziel66 Apr. 24 at 5:54 PM

$TOVX no wonder why pharma companies are slow, but we will see next week

0 · Reply

Zeestallion Apr. 24 at 5:10 PM

$TOVX All my freinds also get on $IMCC. 134% is a 134% positive operating cash flow! @andytran1976

0 · Reply

Stef_Gee Apr. 24 at 3:47 PM

$TOVX 4 days on higher high 👍 (Stock or asset that creates a "higher high" for four consecutive days is exhibiting strong, sustained bullish momentum, often indicating a powerful uptrend where buyers are consistently overcoming sellers. This behavior frequently occurs during breakouts to new all-time highs (ATH) or during strong, euphoric rallies where previous resistance levels are broken)

0 · Reply

rwat Apr. 24 at 3:42 PM

$HIMS taking profits isn’t a bad thing. Loaded up on $TOVX

0 · Reply

Stef_Gee Apr. 24 at 3:37 PM

$TOVX Started a swing position here (50%) for the next week Have a GREAT weekend yall ! 🤘😉

0 · Reply

Stockrunners1 Apr. 24 at 3:19 PM

It might take until power hour or after hours but my gut and my chart on $TOVX says .40 gets blown away today.Possibly Monday if todays volume doesnt pick up.

0 · Reply

Why Is Theriva Stock Gaining Monday?

Apr 17, 2026, 4:05 PM EDT - 7 days ago

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

Dec 29, 2025, 8:00 AM EST - 4 months ago

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Oct 24, 2025, 2:31 PM EDT - 6 months ago

Theriva Biologics Provides Response to Unusual Market Action

Oct 16, 2025, 8:11 AM EDT - 6 months ago

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

Oct 6, 2025, 8:00 AM EDT - 7 months ago

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Aug 11, 2025, 8:00 AM EDT - 9 months ago

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

May 14, 2025, 8:40 AM EDT - 1 year ago

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

May 8, 2025, 4:30 PM EDT - 1 year ago

Theriva Biologics Announces Closing of $7.5 Million Public Offering

May 7, 2025, 9:17 AM EDT - 1 year ago

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Mar 19, 2025, 8:10 AM EDT - 1 year ago

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Mar 6, 2025, 4:10 PM EST - 1 year ago

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Mar 5, 2025, 4:05 PM EST - 1 year ago

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Dec 5, 2024, 8:00 AM EST - 1 year ago

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Sep 26, 2024, 9:06 PM EDT - 1 year ago

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Aug 16, 2024, 4:05 PM EDT - 1 year ago

Theriva Biologics Announces Reverse Stock Split

Jul 31, 2024, 8:15 AM EDT - 1 year ago

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

May 23, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

May 14, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Apr 25, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

$Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma$

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Apr 22, 2024, 4:35 PM EDT - 2 years ago

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Mar 25, 2024, 7:30 AM EDT - 2 years ago

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

Feb 7, 2024, 8:00 AM EST - 2 years ago

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Jan 16, 2024, 8:00 AM EST - 2 years ago

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 6, 2023, 4:05 PM EST - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

Nov 2, 2023, 4:15 PM EDT - 2 years ago

Theriva™ Biologics to Participate in the BIO-Europe Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics to Participate in the Emerging Growth Conference

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Aug 1, 2023, 4:05 PM EDT - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results

Jun 27, 2023, 4:10 PM EDT - 3 years ago

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer

May 23, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

May 11, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

May 4, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Mar 30, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Mar 24, 2023, 4:05 PM EDT - 3 years ago

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

RoyalImperial Apr. 25 at 5:32 PM

0 · Reply

AssasinLife Apr. 25 at 1:58 AM

$MITQ nice volume came here today, something is obv brewing. Usually news comes along, they haven't released one a while 👀 $RPGL $TOVX .

0 · Reply

TheDipMaster Apr. 25 at 1:21 AM

0 · Reply

RoyalImperial Apr. 24 at 9:47 PM

1 · Reply

Raziel66 Apr. 24 at 5:54 PM

$TOVX no wonder why pharma companies are slow, but we will see next week

0 · Reply

Zeestallion Apr. 24 at 5:10 PM

$TOVX All my freinds also get on $IMCC. 134% is a 134% positive operating cash flow! @andytran1976

0 · Reply

Stef_Gee Apr. 24 at 3:47 PM

0 · Reply

rwat Apr. 24 at 3:42 PM

$HIMS taking profits isn’t a bad thing. Loaded up on $TOVX

0 · Reply

Stef_Gee Apr. 24 at 3:37 PM

$TOVX Started a swing position here (50%) for the next week Have a GREAT weekend yall ! 🤘😉

0 · Reply

Stockrunners1 Apr. 24 at 3:19 PM

It might take until power hour or after hours but my gut and my chart on $TOVX says .40 gets blown away today.Possibly Monday if todays volume doesnt pick up.

0 · Reply